ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,721.60
0.00%
S&P ASX All Technology
3,063.30
0.00%
Brent Oil
83.975
0.50%
US Dollar vs AUD
1.51055
-0.66%
Bitcoin
62,594.50
2.30%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) News

IGC

IGC Pharma (IGC)

IGC Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:IGC
DateTimeSourceHeadlineSymbolCompany
16/04/202421:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202423:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
27/03/202406:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
21/03/202402:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202422:00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
13/03/202406:00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
29/02/202405:00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
24/02/202404:01Business WireIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetAMEX:IGCIGC Pharma Inc
17/02/202411:05Business WireIGC Pharma Reports Third Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
15/02/202408:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
02/02/202401:20Business WireIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
01/02/202408:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
24/01/202401:20Business WireIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’sAMEX:IGCIGC Pharma Inc
18/01/202401:20Business WireIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s TrialAMEX:IGCIGC Pharma Inc
09/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
30/12/202308:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
20/12/202301:20Business WirePatent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’sAMEX:IGCIGC Pharma Inc
14/12/202301:30Business WireIGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024AMEX:IGCIGC Pharma Inc
07/12/202300:30Business WireIGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsAMEX:IGCIGC Pharma Inc
22/11/202300:30Business WireIGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesAMEX:IGCIGC Pharma Inc
14/11/202300:00Business WireIGC Pharma Reports Second Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
10/11/202309:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
28/10/202308:21Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
28/10/202307:38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
20/10/202306:30Business WireIGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyAMEX:IGCIGC Pharma Inc
06/10/202315:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
30/09/202307:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
22/08/202304:30Business WireIGC Announces Results of its 2023 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
22/08/202302:44Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
14/08/202322:30Business WireIGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsAMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Your Recent History

ASX
AMP
AMP
FX
AUDCAD
AUD vs CAD
NASDAQ
MSFT
Microsoft
NASDAQ
AAPL
Apple
COIN
ETHUSD
Ethereum
ASX
FMG
Fortescue
ASX
XFL
S&P ASX 50
FTSE
UKX
FTSE 100
ASX
WBC
Westpac Banking
FX
AUDJPY
AUD vs Yen
ASX
CBA
Commonwealth Bank Of Aus...
ASX
WPL
Woodside Petroleum
FX
AUDUSD
AUD vs US Dollar
ASX
XTO
S&P ASX 100
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved